Mammoth Biosciences is a biotechnology company focused on leveraging its proprietary ultracompact CRISPR systems to develop potential long-term curative therapies for patients with life-threatening and debilitating diseases.

Founded by CRISPR pioneer and Nobel laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington, our company’s ultracompact systems are designed to be more specific and enable in vivo gene editing in difficult to reach tissues utilizing both nuclease applications and new editing modalities beyond double stranded breaks, including base editing, reverse transcriptase editing, and epigenetic editing.

Our company is building out its wholly owned pipeline of potential in vivo gene editing therapeutics and capabilities and has partnerships with leading pharmaceutical and biotechnology companies to broaden the reach of our innovative and proprietary technology platform. Mammoth’s deep science and industry experience, along with a robust and differentiated intellectual property portfolio, have enabled the company to further our mission to transform the lives of patients and deliver on the promise of CRISPR technologies.

Selected Investors

Validating partnerships with sophisticated collaborators accelerate our evolution

  • Regeneron

    • Over a decade of investment and experience in genetic medicines through Regeneron Genetics Center
    • Company that has developed and commercialized many therapies for serious diseases
    • Complementary AAV technology

    Key Terms:

    • Multiple in-vivo indications
    • $100M Upfront and Equity investment
    • $370 million per target in development, regulatory and commercial milestone payments
    • Royalty rates ranging from single digits to mid teens on future net sales
    • Right to opt-in to co-funding and sharing profits on a majority of collaboration programs

  • Vertex

    • First approved CRISPR based therapy
    • High-science company with successful track record in developing therapies for highly complex diseases
    • Complementary AAV delivery technology (Affinia)

    Key Terms:

    • Two in vivo indications
    • Upfront payments and investments of $40 million
    • Up to $650 million in potential future payments
    • Tiered royalties on net sales

  • Bayer

    • Early JV in CRISPR space (Casebia)
    • Company (AskBio) with long history in development of genetic medicines and access to various delivery technologies
    • Complementary AAV delivery technology (AskBio acquisition) and LNP technology.

    Key Terms:

    • Five in vivo indications, starting with liver targets
    • Upfront payment of $40 million
    • >$1 billion in potential future payments
    • Tiered royalties up to low double-digits

Leadership

Our leadership team has a legacy of cutting edge scientific research and business achievement.

  • Gabor Veres, Ph. D.

    SVP of Translational Sciences

  • Aruna Perera, Ph. D.

    VP of Technical Operations

  • Rachel Herder, Ph. D.

    VP IP & Assoc. General Counsel

  • Dave Kuo

    SVP of People

  • Adam Rodriguez

    SVP Finance

  • Laura Smith

    VP, Tx Chief of Staff

Board Members

  • Trevor Martin, Ph. D.

    Co-founder, Chief Executive Officer

  • Janice Chen, Ph. D.

    Co-founder, Chief Technology Officer

  • Jeff Huber

    Chair | Triatomic Capital

  • Jeremy Green

    Redmile Group

  • Min Cui, Ph. D.

    Decheng Capital

  • Ursheet Parikh

    Mayfield

  • Maneesh Jain, Ph. D.

    CEO/Co-founder Mirvie

Scientific Advisory Board

  • Jennifer Doudna, Ph. D.

    Chair | Co-Founder | Professor, UC Berkeley

  • Brigit Riley, Ph. D.

    Former CSO, Adverum Biotechnologies

  • Charles Albright, Ph. D.

    CSO, Affinia Therapeutics

  • Kathie Bishop, Ph. D.

    CSO & SVP, Acadia Pharmaceuticals

  • Dinah Sah, Ph. D.

    Former CSO, Voyager Therapeutics

Selected Awards

EY Entrepreneur of the Year Regional Winner and National Finalist 2021Learn More In Vivo’s 2024 Rising LeadersLearn More Endpoints 11 Biopharma's Most Promising Startups in 2022Learn More Fast Company Next Big Things in Tech 2022Learn More BioSpace's 2023 Best Places to WorkLearn More MIT Technology Review 35 Innovators Under 35Learn More Endpoints Top 20 Women in BiopharmaLearn More Forbes "30 Under 30"Learn More

Contact Us

Email: info@mammothbiosci.com
Partnerships: partner@mammothbiosci.com
Phone: +1-650-294-8583

Mammoth Biosciences, Inc.
1000 Marina Blvd.
Brisbane, CA 94005

For press inquiries please contact media@mammothbiosci.com

Trevor Martin

Co-founder, Chief Executive Officer

Dr. Trevor Martin founded Mammoth Biosciences with the mission to enable the next generation of CRISPR-based synthetic biology products across therapeutics and diagnostics, including a novel class of affordable, effective, and rapid CRISPR-enabled molecular diagnostics that allow individuals worldwide to better understand their health and a novel family of CRISPR Cas14 proteins that can enable in-vivo editing.

Trevor earned his BA from Princeton University and his PhD in Biology from Stanford. His work has been featured in outlets including FiveThirtyEight and The Atlantic. He is the featured healthcare honoree on the Forbes 30 Under 30 list, is on Fortune’s 40 Under 40 list, and is a Malaria No More “10 to END” innovator.

Janice Chen

Co-founder, Chief Technology Officer

As co-founder and Chief Technology Officer of Mammoth Biosciences, Janice leads the Applied program by implementing CRISPR-based DETECTR technology towards disease detection and other areas. Janice received her Ph.D. in Molecular and Cell Biology in Jennifer Doudna's lab at UC Berkeley. She has authored multiple publications and patents related to CRISPR mechanism and technologies, and co-invented the programmable CRISPR-based detection technology called DETECTR. Janice was selected as a 2019 Forbes 30 Under 30 in Healthcare, and delivered a TEDx talk in 2018 on the potential for CRISPR to democratize diagnostics.

Lucas Harrington

Co-founder, Chief Science Officer

As co-founder and Chief Science Officer of Mammoth Biosciences, Lucas drives the development of next-generation CRISPR products and leads the scientific research program for new discoveries. He focuses on harnessing microbial diversity to build novel CRISPR applications for DNA detection and genome editing. At UC Berkeley, Lucas worked in Jennifer Doudna’s lab and authored multiple scientific papers, the latest of which features his discovery of the newest Cas system to date, Cas14, in Science. He received a BS in Chemistry from Washington University in St. Louis, where he researched bacterial photosynthesis.

Jennifer Doudna

Co-founder, Chair of Scientific Advisory Board

As an internationally renowned professor of Chemistry and Molecular and Cell Biology at U.C. Berkeley, Doudna and her colleagues rocked the research world in 2012 by discovering a simple way of editing the DNA of any organism using an RNA-guided protein found in bacteria, known as CRISPR. Doudna is an Investigator with the Howard Hughes Medical Institute and a member of the National Academy of Sciences, the National Academy of Medicine, the National Academy of Inventors and the American Academy of Arts and Sciences. She is also a Foreign Member of the Royal Society and has received many other honors including, the Breakthrough Prize in Life Sciences, the Heineken Prize, the BBVA Foundation Frontiers of Knowledge Award and the Japan Prize.

Elaine Sun

Chief Financial Officer and Chief Operating Officer

Elaine joined Mammoth from Halozyme Therapeutics, where she was SVP and Chief Financial Officer of a profitable, commercial-stage biotechnology company. Prior to Halozyme, she served as Chief Financial Officer and Chief Strategy Officer at SutroVax (now Vaxcyte), a developer of next-generation pneumococcal conjugate vaccines. Elaine brings with her 25 years of experience in the life sciences industry, including building and growing both private and public companies. While at SutroVax, she provided strategic, operational and financial leadership for a rapidly growing organization, including establishing innovative supply partnership agreements. Previously, Elaine served as Managing Director and Head of West Coast Healthcare at Evercore Partners and Managing Director at Merrill Lynch. Over her investment banking career, she led and played key roles in a broad range of pharmaceutical, biotechnology and medical device M&A and financing transactions valued in excess of $50 billion. She currently serves on the Board of Directors of Dynavax Technologies and previously served on the Board of Directors of Cirius Therapeutics. Elaine received her BA from Wellesley College and MBA from Harvard Business School.

Ted Tisch

Chief Agility Officer

Ted is the Chief Agility Officer at Mammoth Biosciences after two and half years of building the infrastructure as COO and is focused on implementing agile processes, systems and structure to support the internal technical teams. Previously, as COO at Synthego Corporation, he built the product management, commercial, and manufacturing operations functions as the company progressed from Series A to Series D funding. Ted served as Vice President-General Manager for the Protein Function Division at Bio-Rad Laboratories with global P&L responsibilities spanning multiple proteomics and molecular biology businesses.

Phil Tinmouth

Chief Business and Strategy Officer

Phil’s decades of biopharmaceutical industry experience include a near 20-year career at Vertex Pharmaceuticals, where he played a key role in helping drive the company’s growth. As Vice President and Head of Business Development, Phil built a dynamic team of deal and alliance professionals that executed approximately 30 external deals and collaborations, yielding multiple clinical candidates. While at Vertex, Phil served on multiple committees and teams as the company grew from roughly 300 employees with a market cap of $800 million to well over 3,000 employees and a market cap of more than $50 billion. Prior to Vertex, Phil was a senior manager at Bain & Company in Boston where he advised pharma and biotech clients on growth strategies for over five years. Phil received his bachelor’s degree in mechanical engineering from Queen’s University in Canada, and his MBA from Harvard Business School.

Siang Chin

General Counsel

Siang has an extensive career guiding legal strategy at leading biotechnology, life sciences, and medtech companies — successfully executing transformational transactions and navigating complex regulatory and intellectual property matters. Siang was previously General Counsel of Affymetrix, Inc., where she was part of an executive team that drove growth, profitability, and the company’s acquisition by Thermo Fisher Scientific in 2016. In her most recent position as Vice President and Assistant General Counsel at Intuitive Surgical, she led and grew the corporate, commercial, and compliance legal functions and was instrumental in executing the company’s strategic acquisitions, joint ventures, and key collaborations. Siang received her Bachelor of Laws from King’s College London and her Master of Laws from Georgetown University.